Indeed, individual oncogenic RAS (oncRAS) mutations affecting all three RAS genes (HRAS, KRAS, and NRAS) occur in up to 42% of ERMS [9–11]. This evidence concerns the gene HRAS and embryonal rhabdomyosarcoma.